Key Points
One of the more bullish analysts tracking the company reiterated her enthusiastic buy recommendation on the biotech.
She has flagged it as one of her firm's best stock ideas for this year.
- 10 stocks we like better than Edgewise Therapeutics ›
As investors, we should never underestimate the power of a convincing buy recommendation from an analyst. That was the dynamic behind the impressive rise of Edgewise Therapeutics (NASDAQ: EWTX) stock on Monday; after a pundit who's been tracking the biotech for some time reiterated her bullish view on its potential, investors traded it up by 4% on the day. That crushed the 0.5% increase of the bellwether S&P 500 index.
A bull stays the course
The analyst in question was Piper Sandler's Yasmeen Rahimi. Monday morning, she reiterated her overweight recommendation on Edgewise's equity and her $51 per share price target.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
In fact, according to reports, Rahimi considers Edgewise to be one of Piper Sandler's best stock ideas for this year. This conviction centers around the company's leading cardiovascular drug candidate, EDG-7500, a treatment that targets a genetic heart condition called hypertrophic cardiomyopathy (HCM).
The treatment is currently in a Phase 2 clinical trial, with a readout expected in the second quarter of this calendar year. In the analyst's view, its novel functionality sets it apart from HCM treatments currently on the market, which should give it an edge when and if it is approved for commercialization.
A muscular development effort
That's not the only ace up Edgewise's sleeve, in Rahimi's view. She wrote that several of the company's other pipeline programs have solid potential, and I'd readily agree. In addition to those cardiovascular drugs, the company is also well advanced in developing Sevasemten, a muscular dystrophy treatment currently well advanced in the development cycle.
Should you buy stock in Edgewise Therapeutics right now?
Before you buy stock in Edgewise Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Edgewise Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,299!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,136,601!*
Now, it’s worth noting Stock Advisor’s total average return is 914% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 9, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
